Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)

被引：0
|
作者：
Portales, F. [1 ]
Philip, P. A. [2 ]
Hammel, P. [3 ]
Buscaglia, M. [4 ]
Pazo-Cid, R. [5 ]
Manzano Mozo, J. L. [6 ]
Kim, E. S. [7 ]
Dowden, S. [8 ]
Zakari, A. [9 ]
Borg, C. [10 ]
Terrebonne, E. [11 ]
Rivera Herrero, F. [12 ]
Li, J. Shiansong [13 ]
Ong, T. J. [14 ]
Nydam, T. [14 ]
Lacy, J. [15 ]
机构：
[1] Inst Reg Canc Montpellier ICM, Digestif, Montpellier, France
[2] Karmanos Canc Inst, Dept Oncol, Detroit, MI USA
[3] Hop Beaujon, Gastroenterol, Clichy, France
[4] Azienda Osped Univ San Martino, Med Oncol, Genoa, Italy
[5] Hosp Miguel Servet, Med Oncol, Zaragoza, Spain
[6] Hosp Badalona Germans Trias & Pujol, Med Oncol, Barcelona, Spain
[7] Levine Canc Inst, Med Oncol, Charlotte, NC USA
[8] Tom Baker Canc Clin, Med Oncol, Calgary, AB, Canada
[9] Florida Hosp Canc Inst, Gastro Intestinal Canc Program, Orlando, FL USA
[10] Ctr Hosp Belfort Montbeliard, Med Oncol, Montbeliard, France
[11] Hosp Haut Leveque, Med Oncol, Giround, France
[12] Hosp Univ Marques de Valdecilla, Med Oncol, Santander, Spain
[13] Celgene Corp, Biostat, Summit, NJ USA
[14] Celgene Corp USA, Med Affairs, Summit, NJ USA
[15] Yale Canc Ctr, Med Oncol, New Haven, CT USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
730P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).
    Hammel, Pascal
    Lacy, Jill
    Portales, Fabienne
    Sobrero, Alberto F.
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Mozo, Manzano
    Terrebonne, Eric
    Dowden, Scot D.
    Li, Jack Shiansong
    Ong, Teng Jin
    Nydam, Thom
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [2] nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial
    Philip, P. A.
    Lacy, J.
    Portales, F.
    Sobrero, A.
    Pazo-Cid, R.
    Manzano Mozo, J. L.
    Kim, E. S.
    Dowden, S.
    Zakari, A.
    Borg, C.
    Terrebonne, E.
    Rivera Herrero, F.
    Shiansong Li, J.
    Ong, T. J.
    Nydam, T.
    Hammel, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).
    Lacy, Jill
    Portales, Fabienne
    Hammel, Pascal
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Kim, Edward Jae-hoon
    Dowden, Scot D.
    Borg, Christophe
    Sastre, Javier
    Bathini, Venu Gopal
    Terrebonne, Eric
    Lopez-Trabada, Daniel
    Rivera, Fernando
    Asselah, Jamil
    Damiani, Azzurra
    Hwang, Jimmy J.
    Ong, Teng Jin
    Nydam, Thom
    Li, Jack Shiansong
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [4] International phase II trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients with locally advanced pancreatic cancer (LAPC): LAPACT
    Philip, P.
    Kayitalire, L.
    Nydam, T.
    Penenberg, D.
    Hammel, P.
    ANNALS OF ONCOLOGY, 2015, 26
  • [5] LAPACT: An open-label, multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).
    Philip, Philip Agop
    Lacy, Jill
    Dowden, Scot D.
    Sastre, Javier
    Bathini, Venu Gopal
    Cardin, Dana Backlund
    Ma, Wen Wee
    Sobrero, Alberto F.
    Koski, Sheryl L.
    Borg, Christophe
    Tonini, Giuseppe
    Rivera, Fernando
    Hwang, Jimmy J.
    Knoble, Jeanna L.
    Al Baghdadi, Tareq
    Saif, Wasif M.
    Meiri, Eyal
    Kayitalire, Louis
    Li, Jack
    Hammel, Pascal
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [6] Gemcitabine (G) plus nab-paclitaxel (nab-P) plus chemoradiation (CRT) in locally advanced pancreatic cancer (LAPC)
    Olowokure, Olugbenga Olanrele
    Bedoya, Ivan Dario
    Mierzwa, Michelle Lynn
    Torregroza, Maria Patricia
    Dwivedi, Alok Kumar
    Wang, Jiang
    Smith, Milton T.
    Schmulewitz, Nathan
    Kucera, Stephen
    Choe, Kyuran Ann
    Ristagno, Ross
    Rudich, Steven
    Sussman, Jeffrey J.
    Ahmad, Syed A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] The international, open-label, multicenter phase 2 LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients with locally advanced pancreatic cancer (LAPC)
    Pascal, Hammel
    Jill, Lacy
    Fabienne, Portales
    Alberto, Sobrero
    Beatriz, Garca-Paredes
    Edward, Kim
    Fernando, Rivera
    Jose Luis, Manzano
    Eric, Terrebonne
    Venu, Bathini
    Scot, Dowden
    Jamil, Asselah
    Jack, Shiansong Li
    Thomas, Nydam
    Louis, Kayitalire
    Philip, Philip
    ANNALS OF ONCOLOGY, 2016, 27 : 78 - 79
  • [8] Phase II LAPACT Trial of Nab-Paclitaxel Plus Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
    Bekaii-Saab, Tanios
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 9 - 10
  • [9] Gemcitabine (Gem) and nab-paclitaxel (nab-P) in patients (pts) with refractory advanced pancreatic cancer
    Palacio, Sofia
    Akunyili, Ikechukwu Immanuel
    Ernani, Vinicius
    Macintyre, Jessica
    Merchan, Jaime R.
    Pollack, Terri
    Reis, Isildinha
    Restrepo, Maria H.
    Lima, Caio Max S. Rocha
    Hosein, Peter Joel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [10] Gemcitabine plus Nab-Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC)
    Olowokure, Olugbenga
    Torregroza-Sanchez, Maria Patricia
    Bedoya-Apraez, Ivan Dario
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2013, 4 (02) : E16 - E18
12345